Global Endovascular Stent Grafts Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Endovascular Stent Grafts Market Size

• The global endovascular stent grafts market size was valued at USD 1.20 billion in 2024 and is expected to reach USD 1.94 billion by 2032, at a CAGR of 6.20% during the forecast period
• The market growth is largely fueled by the increasing prevalence of aortic aneurysms, particularly abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA), coupled with the rising demand for minimally invasive treatment options. The shift from open surgical repair to endovascular aneurysm repair (EVAR and TEVAR) is significantly accelerating the adoption of endovascular stent graft solutions across both developed and developing regions
• Furthermore, technological advancements in stent graft design—such as fenestrated, branched, and low-profile systems—are improving procedural outcomes and expanding the patient pool eligible for endovascular repair. These innovations are establishing endovascular stent grafts as the preferred therapeutic approach for vascular surgeons, thereby driving sustained market expansion. The convergence of improved imaging, navigation systems, and hybrid operating suites further reinforces the market’s growth trajectory

Endovascular Stent Grafts Market Analysis

• Endovascular stent grafts, used in the minimally invasive treatment of aneurysms and other vascular conditions, are becoming increasingly essential in modern vascular surgery due to their ability to reduce operative trauma, recovery time, and overall complication rates. These devices allow for precise deployment within blood vessels and offer improved outcomes compared to open surgery
• The escalating demand for endovascular stent grafts is primarily fueled by the rising global prevalence of aortic aneurysms, increasing aging population, advancements in imaging and catheter-based technologies, and growing preference for less invasive procedures
• North America dominated the endovascular stent grafts market with the largest revenue share of 38.2% in 2024, supported by a robust healthcare infrastructure, early adoption of innovative vascular technologies, and a high burden of cardiovascular diseases. The U.S. remains the largest contributor within the region, driven by increasing procedure volumes, favorable reimbursement policies, and a strong pipeline of product innovations by key medical device companies
• Asia-Pacific is expected to be the fastest-growing region, with a projected CAGR of 7.9% from 2025 to 2032, owing to increasing healthcare expenditure, expanding patient awareness, and the growing prevalence of lifestyle-related cardiovascular diseases in rapidly urbanizing nations such as China, India, and South Korea
• The Synthetic segment dominated the market with the largest revenue share of 62.5% in 2024, attributed to its widespread availability, cost-effectiveness, and durability. Synthetic stent grafts, typically made of materials such as polyester or expanded polytetrafluoroethylene (ePTFE), are widely used in endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR) due to their high tensile strength and compatibility with various anatomical structures

Report Scope and Endovascular Stent Grafts Market Segmentation 

Endovascular Stent Grafts Market Trends

“Technological Advancements and Shift Toward Minimally Invasive Procedures”

• A significant and accelerating trend in the global endovascular stent grafts market is the increasing adoption of minimally invasive vascular interventions, which are gradually replacing traditional open surgical procedures due to faster recovery, reduced hospital stays, and lower procedural risks
• Endovascular stent grafts are becoming the preferred choice for treating aortic aneurysms and dissections, as they offer precise deployment, reduced intraoperative blood loss, and fewer complications. This shift is being strongly supported by advancements in catheter-based delivery systems, hybrid imaging guidance, and patient-specific graft customization
• The emergence of branched and fenestrated stent grafts has expanded the treatable population, especially for patients with complex aortic anatomies that were previously inoperable using conventional endovascular methods. These innovative grafts allow for better alignment with aortic branches, preserving blood flow while ensuring aneurysm exclusion
• Furthermore, the growing use of intravascular ultrasound (IVUS), 3D imaging, and robotic-assisted techniques is enhancing the accuracy and safety of endovascular procedures, prompting healthcare providers to increase their adoption across both high-income and developing countries
• The global burden of cardiovascular diseases, particularly aneurysmal conditions, continues to rise with an aging population, sedentary lifestyles, and increased tobacco use—amplifying demand for effective, low-risk treatment options such as endovascular stent grafts
• As healthcare systems aim to improve procedural efficiency and patient outcomes, manufacturers are focusing on the development of next-generation grafts with improved durability, flexibility, and adaptability to varied anatomical profiles, reinforcing the market’s upward trajectory across hospitals and ambulatory surgical centers globally

Endovascular Stent Grafts Market Dynamics

Driver

“Growing Need Due to Rising Cardiovascular Disease Burden and Preference for Minimally Invasive Procedures”

• The increasing global incidence of aortic aneurysms and peripheral artery disease, along with the aging population, is significantly driving the demand for endovascular stent grafts
  • For instance, in April 2024, Medtronic announced a breakthrough in its endovascular aneurysm repair (EVAR) platform with the introduction of its next-generation stent graft delivery system designed to improve deployment precision and reduce procedural complications. Such innovations are expected to support the endovascular stent grafts industry growth during the forecast period
• As patients and healthcare providers increasingly seek less invasive alternatives to open surgery, endovascular stent grafts offer notable advantages—such as reduced hospital stays, faster recovery, and lower morbidity and mortality rates
• In addition, advancements in imaging and catheter technologies are enhancing the precision and success rate of stent graft procedures, making them more accessible for complex anatomies
• Growing awareness among clinicians regarding the benefits of early aneurysm screening and treatment, as well as increasing investments in vascular infrastructure in emerging markets, further contribute to market expansion

Restraint/Challenge

“High Cost of Procedures and Device-Related Complications”

• The high cost of endovascular stent graft procedures and associated devices remains a significant barrier to market adoption, especially in low- and middle-income countries with limited healthcare budgets
  • For instance, reimbursement challenges and cost-containment measures in public healthcare systems often make EVAR and TEVAR (thoracic endovascular aneurysm repair) procedures financially unfeasible for certain patient populations
• Another concern is the potential for post-procedural complications, such as endoleaks, stent migration, or device fatigue, which can necessitate reintervention and impact long-term outcomes. This reduces confidence among some vascular surgeons regarding broader adoption for complex or borderline anatomies
• To address these concerns, companies are focusing on innovations that improve graft flexibility, conformability, and fixation systems, while also working on cost-effective designs that enhance affordability
• Increased training of interventional radiologists and vascular surgeons, along with the adoption of value-based care models and expanded insurance coverage, will be critical in overcoming these limitations and ensuring sustained growth in the Endovascular Stent Grafts market

Endovascular Stent Grafts Market Scope

The market is segmented on the basis of type, and end user.

• By Type

On the basis of type, the endovascular stent grafts market is segmented into synthetic, biological, and biosynthetic. The synthetic segment dominated the market with the largest revenue share of 62.5% in 2024, attributed to its widespread availability, cost-effectiveness, and durability. Synthetic stent grafts, typically made of materials such as polyester or expanded polytetrafluoroethylene (ePTFE), are widely used in endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR) due to their high tensile strength and compatibility with various anatomical structures.

The biological segment is expected to witness the fastest CAGR of 9.4% from 2025 to 2032, driven by increasing interest in biocompatible materials that reduce immune response and promote better healing outcomes. These grafts, derived from natural tissues (e.g., bovine pericardium or human cadaveric vessels), are gaining traction particularly in high-risk patients or complex anatomical cases where synthetic grafts may not be ideal.

• By End User

On the basis of end user, the endovascular stent grafts market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment accounted for the largest revenue share of 68.3% in 2024, owing to the high volume of vascular surgeries, availability of skilled vascular surgeons, and the presence of advanced imaging and operating room infrastructure. Hospitals remain the primary centers for both elective and emergency endovascular procedures.

The ambulatory surgical centers segment is anticipated to exhibit the fastest growth at a CAGR of 8.7% from 2025 to 2032, as outpatient-based vascular interventions gain popularity due to cost-effectiveness, shorter wait times, and faster patient turnaround. Technological advancements and reimbursement support in developed countries are further encouraging the shift toward minimally invasive procedures performed in ASCs.

Endovascular Stent Grafts Market Regional Analysis

• North America dominated the endovascular stent grafts market with the largest revenue share of 38.2% in 2024, driven by the high prevalence of abdominal and thoracic aortic aneurysms, advanced healthcare infrastructure, and increased adoption of minimally invasive surgical procedures
• Patients and healthcare providers in the region increasingly prefer endovascular techniques due to reduced hospital stays, fewer complications, and faster recovery times compared to open surgeries
• This growth is further bolstered by favorable reimbursement policies, an aging population, and strong R&D activities by key medical device manufacturers, positioning North America as a global leader in the adoption of endovascular solutions

U.S. Endovascular Stent Grafts Market Insight

The U.S. endovascular stent grafts market captured the largest revenue share of 75% in 2024 within North America, fueled by a rising incidence of aortic aneurysms, rapid technological advancements, and increasing preference for endovascular aneurysm repair (EVAR) over traditional open surgery. Hospitals and outpatient surgical centers are increasingly equipping themselves with advanced imaging tools and hybrid operating rooms, further supporting market growth. In addition, the strong presence of leading market players such as Medtronic, Cook Medical, and W. L. Gore & Associates continues to drive innovation and accessibility in the U.S. market.

Europe Endovascular Stent Grafts Market Insight

The Europe endovascular stent grafts market is projected to expand at a substantial CAGR during the forecast period, driven by a rising aging population, greater awareness of aneurysm-related conditions, and the growing shift toward minimally invasive procedures. Countries such as Germany, France, and the U.K. are witnessing increased procedural volumes, supported by public healthcare programs and advancements in stent graft materials and customization. In addition, ongoing clinical research and collaborations across European healthcare institutions are facilitating the adoption of newer endovascular techniques and devices across diverse hospital settings.

U.K. Endovascular Stent Grafts Market Insight

The U.K. endovascular stent grafts market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by government-led initiatives focused on reducing the cardiovascular disease burden and improving patient access to innovative surgical options. The increasing availability of trained vascular specialists, expanding hybrid operating facilities, and investment in early diagnosis programs are contributing to the rising demand for EVAR and TEVAR procedures across both NHS and private healthcare sectors.

Germany Endovascular Stent Grafts Market Insight

The Germany endovascular stent grafts market is expected to expand at a considerable CAGR, owing to the country’s advanced clinical infrastructure, strong focus on innovation, and high procedural volumes for vascular repair surgeries. The German healthcare system’s emphasis on personalized care and sustainability is promoting the use of custom-fit stent grafts and hybrid procedures. Moreover, collaborations between research institutions and med-tech companies are accelerating product development and clinical adoption of endovascular techniques.

Asia-Pacific Endovascular Stent Grafts Market Insight

The Asia-Pacific endovascular stent grafts market is poised to grow at the fastest CAGR of 7.9% during the forecast period (2025–2032), driven by rapid urbanization, expanding healthcare infrastructure, and rising awareness of minimally invasive treatment options in countries such as China, Japan, and India. The growing burden of vascular diseases, increasing availability of diagnostic tools, and government initiatives to promote advanced treatment access are supporting market growth. Furthermore, the region is becoming a global manufacturing hub for endovascular devices, which is improving affordability and availability across public and private hospitals.

Japan Endovascular Stent Grafts Market Insight

The Japan endovascular stent grafts market is gaining momentum due to the country’s rapidly aging population, a high incidence of aneurysmal conditions, and the strong focus on technological integration in healthcare delivery. The country’s robust medical infrastructure and emphasis on preventive screening are enabling early diagnosis and treatment of aortic aneurysms. Japanese hospitals are increasingly investing in minimally invasive systems, while local manufacturers are introducing advanced stent grafts tailored to the needs of geriatric and high-risk patients.

China Endovascular Stent Grafts Market Insight

The China endovascular stent grafts market accounted for the largest market revenue share in Asia-Pacific in 2024, supported by rapid healthcare modernization, a growing middle-class population, and high rates of cardiovascular disease. Government-led health reforms and screening programs are facilitating early aneurysm detection and increasing the demand for endovascular solutions in both urban and rural hospitals. The presence of numerous domestic manufacturers offering cost-effective stent grafts, combined with increased medical tourism and public health investment, is expected to further accelerate market growth in China.

Endovascular Stent Grafts Market Share

The endovascular stent grafts industry is primarily led by well-established companies, including:

• BD (U.S.)
• Cook (U.S.)
• B. Braun SE (Germany)
• Medtronic (Ireland)
• Terumo Corporation (Japan)
• Lombard Medical (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Cardinal Health (U.S.)
• Boston Scientific Corporation (U.S.)
• MicroPort Scientific Corporation (China)
• Merit Medical Systems (U.S.)

Latest Developments in Global Endovascular Stent Grafts Market

• In June 2025, Vivasure Medical received CE Mark approval in Europe for its PerQseal Elite vascular closure system. This bioresorbable technology represents a significant advancement in post-procedure closure for large-bore arterial access sites. By eliminating permanent implants, the system reduces long-term complications, reinforcing Vivasure's position in the innovative segment of the Endovascular Stent Grafts market
• In June 2025, Nectero Medical was granted two new Category III CPT codes by the American Medical Association for its Endovascular Aneurysm Stabilization Treatment (EAST) system. This minimally invasive platform is designed to reinforce abdominal aortic aneurysms before rupture, improving outcomes in patients not suitable for traditional EVAR. The move signals growing recognition of pre-emptive stent graft strategies in clinical care
• In May 2025, Endospan Ltd. presented promising 30-day results from the TRIOMPHE study for its Nexus aortic arch stent graft system. The data, shared at a major vascular conference, highlighted the device’s safety and effectiveness in managing complex aortic arch pathologies, positioning Endospan at the forefront of next-generation arch repair innovations
• In May 2025, GE HealthCare launched CleaRecon DL, a deep learning-powered CBCT image reconstruction software aimed at enhancing image clarity during endovascular procedures. This tool provides higher-quality imaging with lower radiation doses, enabling more precise placement of stent grafts in complex vascular environments

SKU-69049